Loading…
ABUS
Arbutus Biopharma CorpNasdaqResearch view
Healthcare · Pharmaceutical Preparations · SEC EDGAR FY 2025-12-31
Price history
Interactive · live data via TradingView🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Income$-33.5M
Sales$14.1M
Book/sh$0.39
Cash/sh$0.09
Dividend TTM—
Payout—
Employees—
IPO—
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$11.0M
2021
$39.0M
2022
$18.1M
2023
$6.2M
2024
$14.1M
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-73.5M | $-65.5M | $-78.1M | $-76.3M | $-38.2M |
| Net Income | $-76.2M | $-69.5M | $-72.8M | $-69.9M | $-33.5M |
| Diluted EPS | $-0.83 | $-0.46 | $-0.44 | $-0.38 | $-0.17 |
| Operating Cash Flow | $-67.5M | $-35.4M | $-85.9M | $-64.8M | $-39.6M |
| Free Cash Flow | $-68.3M | $-35.9M | $-86.9M | $-65.0M | $-39.6M |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
Follow the news. Follow the move.
ABUS story timeline
Company updates and connected market context, with the dated price move attached.
1
Stories
0
Direct
COMMUNITY · $ABUS0 theses
POST YOUR TAKE →Related Stocks
Loading peers…
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.